-
11.发明申请COMBINATIONS OF IMIDAFENACIN AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER 审中-公开IMIDAFENACIN和SALIVARY STIMULANTS用于治疗过敏性叶片的组合公开(公告)号：US20120289563A1
公开(公告)日：2012-11-15
申请号：US13467248
申请日：2012-05-09
IPC分类号： A61K31/4178 , A61P13/10
CPC分类号： A61K31/4174 , A61K31/4178 , A61K2300/00
摘要： Disclosed are pharmaceutical compositions comprising a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or pharmaceutically acceptable salt thereof. Also disclosed are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or pharmaceutically acceptable salt thereof.
摘要翻译： 公开了药物组合物，其包含治疗有效量的立即释放或口服崩解的咪达方案，或其药学上可接受的盐和治疗有效量的毛果芸香碱或其药学上可接受的盐。 还公开了治疗患有膀胱过度活动症的患者的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的即时释放或口服崩解的咪达那新或其药学上可接受的盐，以及治疗有效的 毛果芸香碱或其药学上可接受的盐的量。 还公开了减轻患有其中的患者的膀胱过度活动症的副作用的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的即时释放或口服分解的阿米达海星或药学上可接受的 其盐和治疗有效量的毛果芸香碱或其药学上可接受的盐。
-
12.发明申请公开(公告)号：US20120289543A1
公开(公告)日：2012-11-15
申请号：US13467195
申请日：2012-05-09
IPC分类号： A61K31/4725 , A61P13/10
CPC分类号： A61K31/4178 , A61K31/4725 , A61K2300/00
摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
-
13.发明申请公开(公告)号：US20120289530A1
公开(公告)日：2012-11-15
申请号：US13468012
申请日：2012-05-09
CPC分类号： A61K31/46 , A61K31/4178 , A61K2300/00
摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
-
14.发明授权公开(公告)号：US07041640B2
公开(公告)日：2006-05-09
申请号：US10800990
申请日：2004-03-15
申请人： Samuel Broder , Kenneth L. Duchin , Sami Selim
发明人： Samuel Broder , Kenneth L. Duchin , Sami Selim
IPC分类号： A61K31/337
CPC分类号： A61K45/06 , A61K31/00 , A61K31/337 , A61K38/13 , Y02A50/411 , A61K2300/00
摘要： A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.
-
15.发明授权Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents 失效用于增加药剂的口服生物利用度的方法，组合物和试剂盒公开(公告)号：US06245805B1
公开(公告)日：2001-06-12
申请号：US08733142
申请日：1996-10-16
申请人： Samuel Broder , Kenneth L. Duchin , Sami Selim
发明人： Samuel Broder , Kenneth L. Duchin , Sami Selim
IPC分类号： A01N4302
CPC分类号： A61K45/06 , A61K31/00 , A61K31/337 , A61K38/13 , Y02A50/411 , A61K2300/00
摘要： A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.
摘要翻译： 在口服给药药物活性的靶剂，特别是表现出差的或不一致的口服生物利用度（例如紫杉醇，多西紫杉醇或依托泊苷）的抗肿瘤剂或抗肿瘤药物时，增加生物利用度的方法包括向哺乳动物患者口服共同施用 目标剂和口服生物利用度增加剂（例如环孢菌素A，环孢菌素D，环孢菌素F或酮康唑）。 增强剂可以在0.5-24小时口服给药。 在一次或多次剂量的目标试剂口服给药之前，基本上同时与目标试剂或两者在目标试剂之前和基本上同时进行。 治疗患有对具有差的口服生物利用度的靶因子起反应的疾病的哺乳动物患者的方法以及含有这些靶因子的口服剂型，含有生物利用度增强剂和靶剂的组合口服剂型和含有增强剂和靶剂剂型的试剂盒 并且还公开了其共同给药的给药信息。
-
16.发明申请公开(公告)号：US20120289561A1
公开(公告)日：2012-11-15
申请号：US13467230
申请日：2012-05-09
IPC分类号： A61K31/4178 , A61P13/10
CPC分类号： A61K31/222 , A61K31/4178 , A61K2300/00
摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
-
17.发明申请COMBINATIONS OF PROPIVERINE AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER 审中-公开丙肝和唾液乳液联合用于治疗过敏性叶片公开(公告)号：US20120289547A1
公开(公告)日：2012-11-15
申请号：US13468002
申请日：2012-05-09
IPC分类号： A61K31/445 , A61P13/10
CPC分类号： A61K31/445 , A61K31/4178 , A61K2300/00
摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release propiverine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release propiverine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release propiverine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
摘要翻译： 本文公开了包含治疗有效量的延长释放丙哌嗪或其药学上可接受的盐和治疗有效量的毛果芸香碱或其药学上可接受的盐的药物组合物。 本文还公开了治疗患有膀胱过度活动症的患者的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放促丙素或其药学上可接受的盐和治疗有效量 毛果芸香碱或其药学上可接受的盐。 本文还公开了减轻患有其中的患者的膀胱过度活动症的副作用的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放素或药学上可接受的盐 以及治疗有效量的毛果芸香碱或其药学上可接受的盐。
-
18.发明申请公开(公告)号：US20120289539A1
公开(公告)日：2012-11-15
申请号：US13476912
申请日：2012-05-21
IPC分类号： A61K31/439 , A61P13/10
CPC分类号： A61K31/46 , A61K31/4178 , A61K2300/00
摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
-
19.发明申请COMBINATIONS OF TROSPIUM AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER 审中-公开用于治疗过敏性叶片的铁和唾液的组合公开(公告)号：US20120289529A1
公开(公告)日：2012-11-15
申请号：US13467244
申请日：2012-05-09
CPC分类号： A61K31/46 , A61K31/4178 , A61K2300/00
摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
摘要翻译： 本文公开了包含治疗有效量的延长释放蚤或其药学上可接受的盐和治疗有效量的毛果芸香碱或其药学上可接受的盐的药物组合物。 本文还公开了治疗患有膀胱过度活动症的患者的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放蚤或其药学上可接受的盐和治疗有效量 毛果芸香碱或其药学上可接受的盐。 本文还公开了减轻患有其中的患者的膀胱过度活动症的副作用的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放蚤或其药学上可接受的盐 以及治疗有效量的毛果芸香碱或其药学上可接受的盐。
-
20.发明申请公开(公告)号：US20120289568A1
公开(公告)日：2012-11-15
申请号：US13476933
申请日：2012-05-21
IPC分类号： A61K31/4178 , A61P13/10
CPC分类号： A61K31/216 , A61K31/4178 , A61K2300/00
摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.021 秒)
